← Back to home

SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5

Clinical trials for SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5 explained in plain language.

Never miss a new study

Get alerted when new SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5 trials appear

Sign up with your email to follow new studies for SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Promising antibody drug could save lives in rare, deadly lung disease

Disease control Not yet recruiting

This study tests a drug called teclistamab for people with a severe, fast-worsening lung disease linked to anti-MDA5 antibodies. The disease is often fatal, with only about 25% of patients surviving 90 days without a lung transplant. Teclistamab is a bispecific antibody that help…

Matched conditions: SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5

Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control

Last updated Jun 15, 2026 19:05 UTC

SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5

Get alerted when new SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5 trials appear

Promising antibody drug could save lives in rare, deadly lung disease